Dilip Girdharlal Shah, commonly known as DG Shah, was a pharmaceutical executive who founded the Indian Pharmaceutical Alliance . Shah was a member of the first batch of the Indian Institute of Management, Ahmedabad (IIMA), which graduated in 1966. At IIMA, Shah met Smita Dalal, whom he eventually married. They are considered to be the first couple in the history of IIMA. Upon graduation, Shah started worked for Pfizer in 1967. He worked for Pfizer for 30 years as a Commercial Director and eventually became a member of the board of directors for Pfizer-India. Shah's son Anish serves as the MD & CEO for the Mahindra Group .
7-508: The Indian Pharmaceutical Alliance (IPA) is an association of domestic Indian pharmaceutical companies. IPA was founded in August 1999 by Dilip G Shah and six Indian drugmakers: Cipla , Dr. Reddy's , Lupin , Piramal , Ranbaxy , and Wockhardt . IPA was founded to promote the cause of generic drugs in India and has since expanded to include 24 domestic pharmaceutical companies. Sudarshan Jain
14-707: Is the current secretary general of the IPA. The IPA was founded in opposition to the intellectual property rights for drugs defined by the TRIPS agreement . Divya Rajgopal, writing for The Economic Times , notes that: Shah and the IPA became the body that resisted the Intellectual Property Rights that lower income countries like India were forced to sign under the World Trade Organisation's TRIPS agreement. The IPA positioned itself as
21-609: The Indian Pharmaceutical Alliance (IPA) to promote the cause of generic drugs in India and to oppose the drug intellectual property rights defined by the TRIPS Agreement . Divya Rajgopal, writing for The Economic Times , notes that: Shah and the IPA became the body that resisted the Intellectual Property Rights that lower income countries like India were forced to sign under the World Trade Organisation's TRIPS agreement. The IPA positioned itself as
28-632: The shaping of the current Indian patent law, which favours affordable medicines, while also recognising the obligations under the TRIPS agreement". Shah was a member of the official Indian delegation for the World Trade Organization (WTO) ministerial conference at Cancun and testified on behalf of India in an appearance before the United States International Trade Commission (USITC). He also
35-605: The voice of generic drug companies that claimed to represent the interests of Indian drug companies who were bullied under these TRIPS agreement. Recently, the IPA has clashed with the Indian pricing drug regulator, National Pharmaceutical Pricing Authority , over regulating the prices of medicines in India and has worked with drug regulators in the United States about reducing quality issues in Indian pharmaceutical companies. Dilip G Shah In 1999, Shah founded
42-608: The voice of generic drug companies that claimed to represent the interests of Indian drug companies who were bullied under these TRIPS agreement. Shah, few pharma industry veterans recall was at times even more powerful than the Indian CEO's whose interests he represented to the bureaucrats and ministers in Delhi. With the IPA, Shah helped Indian companies communicate with the US Food and Drug Administration (USFDA) and contributed "in
49-724: Was the author of the first book on drug pricing in India. Apart from his work with the IPA, Shah set up a company called Vision Consulting Group to consult about matters of public policy, strategy, and planning and served in a variety of advisory roles. He was the Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms in 2005-07 and 2010-11, a Non-Executive Independent Director of Fresenius Kabi Oncology Limited (formerly Dabur Pharma Limited), an Independent Non-Executive Director at Anuh Pharma Ltd. (October 2007-February 2019),
#566433